Durata hopes to gain approval to market the drug in early 2014, CEO Paul Edick said in an e-mail.
Medicines Co. Treatment
The other similar treatment is oritavancin from Medicines Co., which plans to complete its trials in 2012 and file for approval in 2013, said Michael Mitchell, a company spokesman, in a telephone interview. Analysts expect it to have sales of as much as $300 million for skin infections, Mitchell said.
Paratek Pharmaceuticals Inc.'s omadacycline, licensed to Basel, Switzerland-based Novartis AG, is in late-stage trials for skin infections. The drug is an injectable derivative of tetracycline to be followed by pill forms. Further studies are planned in community-acquired pneumonia and drug-resistant forms of staph and strep bacteria.